PPD Recognized for Exceptional Quality of Collaboration with Clinical Research Sites

Strong site relationships key to quality execution, on-time delivery
for biopharmaceutical customers

WILMINGTON, N.C.–(BUSINESS WIRE)–Pharmaceutical Product Development, LLC (PPD),
a leading global contract research organization (CRO), was named the
winner of the CRO Quality Award from the Association
of Clinical Research Professionals (ACRP) and The
Avoca Group during the recent ACRP annual conference in Nashville,
Tennessee.

PPD’s selection was based on The Avoca Group’s independent research with
investigator sites, which recognized PPD’s industry leadership on
quality outcomes in the design, execution and oversight of clinical
trials, as well as strong communication and partnership skills.

PPD has strategic relationships with sites and site networks across the
globe, providing access to industry-leading numbers of patients and
high-performing sites. Leveraging these partnerships allows for
efficient study startup and execution.

“The strength of our relationships with investigator sites is a critical
factor in delivering on our promise of quality execution and on-time
delivery for our clients,” said David Johnston, Ph.D., executive vice
president of clinical development for PPD. “This accolade reflects our
steadfast commitment to collaborate effectively with our partners at
clinical research sites to help our clients bring high-quality,
life-changing medicines to patients.”

The Avoca Group, which conducted its research over an eight-week period
in early 2019, said site personnel rated PPD highly for responsive,
high-quality communication, clinical research associates with strong
knowledge of the study protocol and several aspects of study execution,
including reliability of clinical supplies, ease of use of the
electronic data capture (EDC) system and study closeout.

“We congratulate PPD for being recognized by site-based clinical
researchers for its ability to work effectively with investigative
sites,” says Jim Kremidas, ACRP’s executive director. “Recognition of
quality partners in the clinical trial community, such as PPD, greatly
supports our mission to promote excellence in clinical research.”

Patricia Leuchten, CEO of The Avoca Group, added: “Congratulations to
PPD and its clinical teams for being recognized by investigative sites
for their dedication to achieving quality outcomes. This award is a
testament to PPD’s commitment to delivering excellence in clinical
research.”

Located in more than 70 countries, ACRP’s 13,000 members work in a
variety of practice settings, roles and specialty areas, with a wide
range of experience in clinical research. With 20 years of experience
providing research and consulting services, The Avoca Group merges deep
institutional knowledge in the foundations of good clinical practice
with leadership in regulatory compliance, quality management and
clinical operations across the evolving clinical trials landscape.

About PPD

PPD is a leading global contract research organization providing
comprehensive, integrated drug development, laboratory and lifecycle
management services. Our clients and partners include pharmaceutical,
biotechnology, medical device, academic and government organizations.
With offices in 48 countries and more than 21,000 professionals
worldwide, PPD applies innovative technologies, therapeutic expertise
and a firm commitment to quality to help clients and partners bend the
cost and time curve of drug development and optimize value in delivering
life-changing therapies to improve health. For more information, visit www.ppdi.com.

Contacts

Media:
Randy Buckwalter
+1 919 456 4425
[email protected]

Investors:
Nate Speicher
+1 910 558 6783
[email protected]